Yamaguchi, Teppei http://orcid.org/0000-0002-8909-5709
Shimizu, Junichi
Hasegawa, Takaaki
Horio, Yoshitsugu
Inaba, Yoshitaka
Hanai, Nobuhiro
Muro, Kei
Hida, Toyoaki
Article History
Received: 26 October 2020
Accepted: 2 August 2021
First Online: 16 August 2021
Declarations
:
: This study was approved by the institutional review board of the Aichi Cancer Center Hospital (No. 2018–1-046). This study was conducted in accordance with the Good Clinical Practice guidelines and the guiding principles detailed in the 1964 Helsinki Declaration, and in keeping with applicable local law(s) and regulation(s). In this retrospective study, the need for consent to participate was deemed unnecessary according to national regulations, “Ethical Guidelines for Medical and Health Research Involving Human Subjects.” The protocol summary was described on the hospital website, and the subjects were provided with the opportunity to opt-out.
: Not applicable.
: Dr. Hida has obtained research grants from Ono Pharmaceutical, Novartis Pharma, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, Nippon Boehringer Ingelheim, Pfizer, Bristol-Meyers Squibb, Clovis Oncology, Eisai, Takeda Bio, Sumitomo Dainippon Pharma, Abbvie, Merck Serono, MSD, Kyowa Hakko Kirin, Daiichi Sankyo, and Astellas, and has received personal fees from Ono Pharmaceutical, Novartis Pharma, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, Nippon Boehringer Ingelheim, Pfizer, Clovis Oncology, and Bristol-Meyers Squibb. Dr. Muro has obtained research grants from Ono Pharmaceutical. All other authors have no conflicts of interest.